Camber Pharmaceuticals Inc
Surya Gandikota has a diverse work experience spanning over two decades. Surya is currently working as the Chief Financial Officer at Camber Pharmaceuticals Inc since October 2023. Prior to this role, Surya served as the Sr. Director and Head of Finance & Accounts at Eywa Pharma Inc from June 2018 to October 2023. From 2012 to 2018, they worked at Mylan in various roles including Director of Global Operations Finance, Director of Product Reporting in Global FP&A, and Director of Core FP&A in Global FP&A. Before joining Mylan, Surya held managerial positions at Matrix Laboratories Limited from 2006 to 2011, starting as a Senior Manager and progressing to General Manager. Surya also worked as a Manager at Dr. Reddy's Laboratories from 2001 to 2006 and as an Assistant Manager at Tecumseh Products India Limited from 1997 to 2001.
Surya Gandikota completed a Bachelor of Science degree in Mathematics, Physics, and Geology from Osmania University in Hyderabad from 1986 to 1989. Later, from 1991 to 1995, Surya pursued further education at the Institute of Cost and Works Accountants of India - CMA, where they obtained a CMA qualification.
This person is not in any offices
Camber Pharmaceuticals Inc
Camber is made up of three groups with one common goal: to be the best generics company in the industry. Camber Pharmaceuticals is rapidly growing and had an industry-leading 28 product approvals in 2022. With the support of our parent company, Hetero, we are poised to have a record number of product approvals and launches in 2023. Hetero, a world leader in API production and vertical manufacturing, is the foundation upon which Camber has maintained a 99% service level for our customers for the past two years. Hetero is investing over $250 million in the next three years in Camber products. The research and development team consists of over 1,000 scientists working to expand the types of drugs Camber offers, including novel delivery systems and complex molecules.